For anyone considering how to treat vitiligo, it helps to know that many of the treatments under evaluation nearly all work the same way. Understanding what that approach does well, and what it leaves unsolved, can help weigh treatment choices with clearer eyes.
If you’ve lived with vitiligo for a while, you’ve probably been told that no one quite knows why it happens. For most of medical history, that was true: it was visible, distressing, and largely unexplained. The good news is that this is gradually changing. While researchers are still working out many pieces of the puzzle, the essentials are now broadly agreed: vitiligo is an autoimmune condition driven by inflammation, in which the immune system destroys the cells that give skin its colour.[1,2] That shift is the key to understanding why many of today’s experimental treatments look the way they do.
What’s actually happening in the skin?
The contemporary picture of vitiligo is increasingly one of mistaken identity inside the skin. The cells that give skin its colour, the melanocytes, come under stress, and a stressed cell sends out distress signals. In vitiligo, the immune system misreads those signals as a threat and responds with far more force than the situation calls for.
From there it becomes a chain reaction. Immune cells release a messenger called interferon-gamma, in effect a chemical alarm, which travels from cell to cell through the skin along a signalling route known as the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. The alarm draws in cytotoxic T cells, immune cells built to destroy, and they reach the melanocytes and kill them. Wherever the pigment cells are lost, the skin turns white in the patches (or lesions) that define the disease.[1,2]
Identifying this inflammation pathway was a genuine breakthrough. It explained, for the first time, how the depigmentation happens at a cellular level, and it handed researchers something they had never really had: a clear target.
Why almost every new treatment is an immune suppressor
If vitiligo is an inflammatory attack relayed along the JAK-STAT pathway, then interrupting that pathway should, in principle, call it off. This logic now drives almost the entire treatment pipeline. The therapies generating much excitement, JAK inhibitors chief among them, work by dampening the very signalling that destroys melanocytes. It is the same reasoning that has made JAK inhibitors successful in other inflammatory diseases, from rheumatoid arthritis to eczema.
But vitiligo is not those diseases. In rheumatoid arthritis, quieting the inflammation is the treatment: calm the attack and you spare the joints. In vitiligo, calming the inflammation stops the attack from spreading, but it does not, by itself, bring the melanocyte (and thus the pigment) back. Repigmentation is a separate, harder job, and that distinction sits underneath almost every question worth asking about how we treat this disease.
As a side note, not every emerging therapy works by broadly suppressing the immune system. Among the most closely watched is a different approach, antibodies that block a signal called interleukin-15 (IL-15), now in mid-stage (phase II) trials. Rather than dampening immune signalling across the board, these target the specific memory cells that keep the attack alive, a meaningfully different strategy, albeit one in fairly early stage.
A different kind of burden, and why it changes the maths
There is a second difference that deserves saying plainly. For all the genuine suffering it causes, vitiligo is not physically incapacitating in the way many inflammatory diseases are. Its defining feature is not the progressive destruction of joints, gut, or organs seen in rheumatoid arthritis or inflammatory bowel disease. Its burden falls most heavily on mental health, self-image, identity, and social life — and that burden can be severe, even devastating. This is not to say the disease stops at the skin: vitiligo is associated with an increased risk of other conditions, most clearly autoimmune thyroid disease and type 1 diabetes,[3] and, more tentatively, cardiovascular and metabolic risk, likely reflecting the shared immune tendencies beneath it.[4,5] The distinction is one of emphasis rather than absolutes: the harm that vitiligo does directly is not, for most people, the kind that makes the body physically ill.
This is not the old dismissal of vitiligo as “just cosmetic”, which we should have retired long ago. It is a different and more careful point: what treatment risks should we be asking patients to accept? And some leading experimental treatments carry notable risks.
Every JAK inhibitor, as a family of drugs that work the same way, carries a Boxed Warning, the most serious caution a regulator can attach to a medicine, flagging risks including serious infections, blood clots, cardiovascular events, certain cancers, and increased mortality.[6] That warning did not originate with the skin. It traces to a large safety study of an oral JAK inhibitor given at higher doses to older rheumatoid arthritis patients, and regulators then applied it to the whole family, which is why even a cream carries it. In the topical vitiligo treatment’s first year on the market, safety monitoring across nearly 14,000 patient-years did not demonstrate any concern from those serious events.[7] The window remains narrow, though: the large real-world dataset covers only that first year, and the longest clinical-trial follow-up runs to roughly three years in a far smaller group.[8] The effects of sustained use over five years or more are not yet known.
Still, it is fair to ask: for a condition whose damage is felt largely in the psyche rather than through physical incapacity, how comfortable are we asking patients to weigh serious systemic risks, especially if the treatment must be taken indefinitely?
The durability problem
Even granting that these treatments can generate a clinical response, and that the repigmentation is real,[9] the effect often does not last once treatment stops. In the pivotal “long-term” data for the approved topical JAK inhibitor (in these trials, “long-term” means two years of follow-up), about 62% of patients who kept applying the cream maintained near-complete facial repigmentation; among those who stopped, only around 39% held even a more modest result, and close to a third relapsed within the year.[10] Across vitiligo therapies of all kinds, roughly 40% of responders relapse within a year of stopping.[11] There is a footnote worth adding: most who relapse regain their response once treatment restarts, which is why a “stop–start” approach is increasingly discussed.[10]
The reason goes to the heart of why this disease is so hard to treat. When treatment quiets the attack and the skin repigments, the immune system does not forget. It leaves behind long-lived sentinels, the tissue-resident memory T cells, that linger in the skin at the old battle sites.[12] The attack is contained, not cleared. This is exactly the gap the newer IL-15 approach hopes to close. Because those memory cells depend on IL-15 to survive, blocking that signal may not just quiet them but deplete them, in principle allowing repigmentation to hold after treatment stops rather than fading. The idea is promising but still unproven in people: the strongest human evidence so far, presented in 2026, showed better repigmentation when an IL-15 blocker was combined with light therapy, while the prospect of lasting, treatment-free remission rests for now on laboratory and animal studies.[17,18,19] It is, in other words, an exploratory approach to the durability problem rather than a settled one, and the kind of genuinely different mechanism the field has been missing.
Is inflammation really the whole problem?
All of this points to a question the field is only beginning to sit with honestly: if quieting the inflammation halts the spread but inconsistently restores colour on its own, is inflammation the main problem left to solve?
The biology suggests not, at least not alone. Bringing pigment back depends on melanocytes regenerating and repopulating the skin, largely from a reservoir of stem cells tucked inside the hair follicles.[13] This is why patches in hairless areas such as the hands and feet respond poorly, and why phototherapy, which helps mobilise those follicular stem cells, remains a cornerstone of treatment and is so often paired with anti-inflammatory drugs.[13,14] Suppressing the attack clears the ground, but something else has to do the rebuilding. Durable repigmentation will come from treatments that address both halves of the problem, not just the inflammatory one.
We need more than one door into treating this disease
Here is the concern that ties it all together. The only pharmaceutical treatment specifically approved for vitiligo is a JAK inhibitor, a topical one, approved only for patients whose vitiligo covers a relatively small area of the body.[15] The systemic therapy furthest along in regulatory review is another JAK inhibitor, and the great majority of candidates in trials are, again, JAK inhibitors, with others that equally seek to suppress other immune components.[16] An enormous amount of hope is being loaded onto a single mechanism, and that is a fragile position for a patient community. A disease this varied, spanning different skin tones, patterns, and ages, with patches that respond alongside patches that never do, is unlikely to be well served by one class of drug, especially one that quiets inflammation with inconsistent repigmentation, may need to be taken indefinitely, and carries a serious class warning. What the field needs is a genuinely diverse toolkit: treatments that work through different mechanisms, that suit the full range of people who live with this condition.
Three pillars, not one
It helps to picture managing vitiligo as resting on three pillars rather than one: reducing the triggers that provoke the attack, quieting the inflammation once it starts, and restoring pigment to skin that has already lost it. Today’s most talked-about treatments are concentrated almost entirely on the middle pillar. That is real progress, but it is merely one pillar of three. The most honest version of where vitiligo treatment stands is that we have learned to quiet the attack, are still learning to prevent it, and have barely begun to master the rebuilding that patients most want to see. That is a far more sophisticated conversation than “is it just cosmetic?” ever was, and a more hopeful one, precisely because it is honest about how much is left to do.
For more thoughtful insights like this, sign up below to receive our newsletters.
- Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–1876. doi:10.1038/jid.2011.463.
- Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23. doi:10.1126/scitranslmed.3007811.
- Liu J, Matangi S, Malempati Y, Nasir A, Rosmarin D. Prevalence and association of autoimmune comorbidities among adults with vitiligo: a systematic literature review and meta-analysis of USA-based studies. Dermatol Ther (Heidelb). 2025. doi:10.1007/s13555-025-01506-y.
- Frączek A, Owczarczyk-Saczonek A, Ludwig RJ, Hernández G, Ständer S, Thaçi D, Zirpel H. Vitiligo is associated with an increased risk of cardiovascular diseases: a large-scale, propensity-matched, US-based retrospective study. EBioMedicine. 2024;109:105423. doi:10.1016/j.ebiom.2024.105423.
- Ataş H, Gönül M. Increased risk of metabolic syndrome in patients with vitiligo. Balkan Med J. 2017;34(3):219–225. doi:10.4274/balkanmedj.2016.1005.
- OPZELURA (ruxolitinib) cream, 1.5%, for topical use: US prescribing information (including Boxed Warning). Wilmington (DE): Incyte Corporation.
- Hu W, et al. Real-world use of ruxolitinib cream: safety analysis at 1 year. Am J Clin Dermatol. 2024;25(1):161–168. doi:10.1007/s40257-023-00840-1.
- Harris JE, Pandya AG, Lebwohl M, et al. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: a randomised controlled trial secondary analysis at 3 years. Skin Health Dis. 2024;4(6):e404. doi:10.1002/ski2.404.
- Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445–1455. doi:10.1056/NEJMoa2118828.
- Harris JE, Papp K, Ezzedine K, Sebastian M, Pandya AG, Seneschal J, Amster M, Shayesteh Alam M, Forman SB, Zdybski J, Nuara A, Kornacki D, Wei S, Passeron T, Rosmarin D. Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study. Br J Dermatol. 2026;194(5):971–973. doi:10.1093/bjd/ljaf519.
- Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970–974. doi:10.1038/jid.2014.527.
- Birlea SA, Costin GE, Roop DR, Norris DA. Trends in regenerative medicine: repigmentation in vitiligo through melanocyte stem cell mobilization. Med Res Rev. 2017;37(4):907–935. doi:10.1002/med.21426.
- Richmond JM, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, Harris JE. Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo. J Invest Dermatol. 2019;139(4):769–778. doi:10.1016/j.jid.2018.10.032.
- Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(7):666–674. doi:10.1001/jamadermatol.2017.0002.
- FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older [Internet]. Silver Spring (MD): US Food and Drug Administration; 2022 Jul 19.
- Harris E. Applications for approval of upadacitinib for vitiligo submitted in the US, Europe. Medscape. 2026 Feb 9.
